Evaxion Biotech A/S (EVAX) News Today $0.92 +0.03 (+3.36%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Evaxion Biotech pursues agreement with EIB to bolster equityDecember 17, 2024 | markets.businessinsider.comEvaxion Biotech: Evaxion establishes new AI-derived precision cancer vaccine conceptDecember 13, 2024 | finanznachrichten.deEvaxion Biotech establishes new Ai-derived precision cancer vaccine conceptDecember 13, 2024 | markets.businessinsider.comEvaxion establishes new AI-derived precision cancer vaccine conceptDecember 12, 2024 | markets.businessinsider.comFinancial Analysis: Cortexyme (NASDAQ:CRTX) vs. Evaxion Biotech A/S (NASDAQ:EVAX)December 12, 2024 | americanbankingnews.comEvaxion Biotech announces strategic milestones for 2025December 10, 2024 | markets.businessinsider.comEvaxion Biotech Unveils 2025 Strategic MilestonesDecember 10, 2024 | markets.businessinsider.comEvaxion announces 2025 milestones reflecting continued strong strategy executionDecember 9, 2024 | markets.businessinsider.comEvaxion Biotech Unveils Precision Cancer Vaccine BreakthroughDecember 3, 2024 | markets.businessinsider.comEvaxion to present preclinical Proof-of-Concept for precision ERV cancer vaccine concept at ESMO Immuno-Oncology CongressDecember 2, 2024 | markets.businessinsider.comEvaxion Biotech files to sell 5.25M American Depositary SharesNovember 19, 2024 | markets.businessinsider.comEvaxion appeals Nasdaq delisting determinationNovember 15, 2024 | uk.investing.comEvaxion receives and appeals delisting determination from Nasdaq, remains committed to Nasdaq listingNovember 13, 2024 | finance.yahoo.comEvaxion Biotech: Evaxion receives and appeals delisting determination from Nasdaq, remains committed to Nasdaq listingNovember 13, 2024 | finanznachrichten.deEvaxion Biotech receives, appeals delisting determination from NasdaqNovember 13, 2024 | markets.businessinsider.comEvaxion Biotech Appeals Nasdaq Delisting DecisionNovember 13, 2024 | markets.businessinsider.comEvaxion Biotech announces preclinical data for CMV vaccine program EVX-V1November 13, 2024 | markets.businessinsider.comEvaxion Biotech: Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1November 12, 2024 | finanznachrichten.deEvaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1November 12, 2024 | globenewswire.comEvaxion Biotech Shows Progress Amid Nasdaq ChallengesNovember 2, 2024 | markets.businessinsider.comEvaxion Biotech Reports Q3 Progress and FinancialsNovember 1, 2024 | markets.businessinsider.comEvaxion announces business update and third quarter 2024 financial resultsOctober 31, 2024 | globenewswire.comEvaxion Biotech to Announce Q3 Financial ResultsOctober 29, 2024 | markets.businessinsider.comEvaxion to announce business update and third quarter 2024 financial results on October 31October 28, 2024 | globenewswire.comEvaxion Biotech Validates AI-Powered Vaccine PredictionsOctober 15, 2024 | msn.comNewly discovered COVID vaccine targets may last longerOctober 11, 2024 | msn.comOTC Markets Hosts Virtual Investor Presentation with Christian Kanstrup, CEO of Evaxion Biotech, and Brad Sorensen, Senior Analyst at Zacks SCROctober 11, 2024 | msn.comStrong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trialsOctober 9, 2024 | markets.businessinsider.comStrong validation of Evaxion's AI-Immunology™ platform in multiple clinical trialsOctober 9, 2024 | globenewswire.comClinical Evidence Supports Advancement of Evaxion's AI-Immunology PlatformOctober 5, 2024 | msn.comEvaxion Biotech Charts Future with Innovative Immune TherapiesOctober 4, 2024 | finance.yahoo.comEvaxion Biotech: Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology platformOctober 3, 2024 | finanznachrichten.deRecent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platformOctober 3, 2024 | globenewswire.comEvaxion Biotech (EVAX) Gets a Buy from Lake StreetSeptember 27, 2024 | markets.businessinsider.comEvaxion significantly expands vaccine development collaboration with MSDSeptember 26, 2024 | globenewswire.comEvaxion Biotech enhances AI vaccine discovery platformSeptember 21, 2024 | uk.investing.comEvaxion Biotech Unveils Enhanced AI Platform for Improved Vaccine DevelopmentSeptember 21, 2024 | msn.comLife Sciences Virtual Investor Forum Presentations Now Available for Online ViewingSeptember 20, 2024 | finance.yahoo.comBuy Rating for Evaxion Biotech Supported by Strong Clinical Results and PIONEER Platform’s PotentialSeptember 20, 2024 | markets.businessinsider.comEvaxion launches improved AI-Immunology™ platform for vaccine antigen predictionSeptember 19, 2024 | globenewswire.comEvaxion Biotech Reports Positive One-Year Results for AI-Designed Cancer VaccineSeptember 18, 2024 | msn.comEvaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01September 16, 2024 | markets.businessinsider.comEvaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01September 9, 2024 | markets.businessinsider.comEvaxion Biotech: Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2September 9, 2024 | finanznachrichten.deEvaxion Biotech: Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01September 9, 2024 | finanznachrichten.deEvaxion Biotech: Clinical Phase 2 Data Supports Clinical Profile Of EVX-01September 9, 2024 | markets.businessinsider.comEvaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2September 9, 2024 | globenewswire.comEvaxion Biotech A/S (NASDAQ:EVAX): Is Breakeven Near?August 30, 2024 | finance.yahoo.comBuy Rating Affirmed for Evaxion Biotech on Strong Financials and Promising Clinical TrialsAugust 16, 2024 | markets.businessinsider.comEarnings To Watch: Home Depot (HD) Reports Q2 Results TomorrowAugust 12, 2024 | uk.finance.yahoo.com Get Evaxion Biotech A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for EVAX and its competitors with MarketBeat's FREE daily newsletter. Email Address Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment (Ad)This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast. Click here for the ticker >>> EVAX Media Mentions By Week EVAX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EVAX News Sentiment▼0.990.60▲Average Medical News Sentiment EVAX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EVAX Articles This Week▼12▲EVAX Articles Average Week Get Evaxion Biotech A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for EVAX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Senti Biosciences News Today MiNK Therapeutics News Today Calidi Biotherapeutics News Today Athira Pharma News Today IN8bio News Today Cognition Therapeutics News Today Finch Therapeutics Group News Today Cyclo Therapeutics News Today NKGen Biotech News Today AIM ImmunoTech News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EVAX) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evaxion Biotech A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Evaxion Biotech A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
